HELLO STONEDINVESTORS> AS I WAS LEAVING THE HF THERE WAS A FLURRY OF ACTIVITY ON ENCENO? NO IDEA. They are having an analyst day- this is the third time in two days that moves have come during these investor day meetings. I find that very interesting primarily because I used to always invest this way!! The guy in the trench coat runs to the wooden phone booth and breathlessly says buy US Steel... But over the years that type of investing doesn't work as well-- Internet kind of ruined it.-still for me it;s an old investing trope I like. It makes sense. Good things are being said. The stock is up./ I got to find this company.
GUMMY UPDATE----------------------- Blend Labs, Inc. (BLND) NYSE - Nasdaq Real Time Price. 1.3250+0.1150 (+9.50%)<------------------- As of 01:52PM EDT. Market open.
THIS WAS $171 MONDAY.// Wingstop Inc. (WING)- YOU CAN'T BE THE SAVANT UNLESS YOU BUY IT!!! 180.91+2.03 (+1.13%) As of 01:57PM EDT. Market open.
UPDATE 1-Soccer-Man Utd start League Cup defence with 3-0 win, * Manchester United beat Crystal Palace at Old Trafford
jah crispy.- Folks it is time we talked about CRISPR > The logic is so clean. But there are some roadblocks one is this drug you have toi take before you can take the CRSPR gene editing drug and that has some side effects. You can't watch these Alien shows and not think Gene editing is the future as in how do we not grow old. There is a critical December Date with the FDA for VRTX and CrispR. This drug exa-cel I beilieve will be approved and it will unlock tons of potential for CrispR. I would say the odds are about 65% to 70% this stock is massively under priced. CRISPR Therapeutics CRISPR Therapeutics is heading for its biggest moment yet. The gene editing specialist is awaiting regulatory decisions on what may become its very first commercialized product. The U.S. Food and Drug Administration (FDA) is set to decide on exa-cel for sickle cell disease in December and on exa-cel for beta thalassemia in March. The company and partner Vertex Pharmaceuticals also submitted the candidate for regulatory approval in the U.K. and Europe. Options to address these particular blood disorders are limited, and exa-cel has been designed as a one-time curative treatment -- so doctors and patients could rush out to give the product a try. In fact, analysts predict it will generate blockbuster revenue. So, even though CRISPR shares profit with Vertex -- 40% for CRISPR and 60% for Vertex -- this represents a big step forward. An approval also would represent a vote of confidence for the gene editing technology CRISPR uses throughout its pipeline. And speaking of the pipeline, CRISPR may not be far from commercializing a second product. The company is studying an immuno-oncology candidate in a phase 2 trial that could support a regulatory submission. NASDAQ: CRSP CRISPR Therapeutics Today's Change (-2.95%) -$1.39 Current Price $45.74 CRSP CRISPR also may generate revenue by licensing its gene editing technology to other companies. For example, Vertex recently bought nonexclusive rights to use CRISPR's gene editing in its type 1 diabetes program. This involved a $100 million up-front payment and potential milestone and royalty payments.
13-1 The Lizard King knows no boundaries and obeys no laws. He acts in a constant state of rebellion and whatever he is being told to do he does the opposite. This rebellious force of nature has compiled an amazing record of S&P long calls. The Lizard King stands at 13-1. All predicted right here in the pages of Elite Trader.
--Flowserve price target raised to $48 from $40 at Mizuho » 06:49 FLS --Amicus price target raised to $19 from $16 at BofA » 06:30 FOLD Elastic price target raised to $90 from $78 at BofA » 06:22 ESTC If this wasn't foreign it would be our Gummy--- Elastic N.V. (ESTC) @$80- NYSE - NYSE Delayed Price. 79.07-2.11(-2.60%) At close: September 28 04:00PM EDT 80.00+0.93(+1.18%)<-------------------- Pre-Market:06:45AM EDT
Femasys price target raised to $13 from $5 at H.C. Wainwright » 06:08 FEMY Femasys Inc. (FEMY) NasdaqCM - NasdaqCM Real Time Price. 1.5200+0.4100(+36.9369%) At close: September 28 04:00PM EDT 2.0090+0.4890(+32.1711%) <---------------- Pre-Market:7:13AM EDT